Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) CEO Ludwig Hantson sold 2,553 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the completion of the transaction, the chief executive officer now directly owns 36,172 shares in the company, valued at approximately $4,399,600.36. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) traded down $2.26 during trading on Thursday, reaching $122.69. 2,090,000 shares of the company traded hands, compared to its average volume of 2,080,000. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34. The stock has a market cap of $27,410.00, a P/E ratio of 54.77, a price-to-earnings-growth ratio of 1.04 and a beta of 1.17. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.12. The company had revenue of $859.00 million during the quarter, compared to analyst estimates of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period last year, the business earned $1.23 EPS. sell-side analysts predict that Alexion Pharmaceuticals, Inc. will post 4.82 earnings per share for the current year.

A number of equities analysts have recently commented on ALXN shares. BMO Capital Markets reissued an “outperform” rating and issued a $173.00 target price (up previously from $168.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. SunTrust Banks reissued a “buy” rating and issued a $180.00 target price (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Leerink Swann reissued an “outperform” rating and issued a $182.00 target price (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. They noted that the move was a valuation call. Deutsche Bank reissued a “buy” rating and issued a $158.00 target price (up previously from $153.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Finally, Royal Bank of Canada started coverage on shares of Alexion Pharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating and a $161.00 target price on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty have issued a buy rating to the company’s stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $153.61.

A number of hedge funds have recently made changes to their positions in ALXN. Robeco Institutional Asset Management B.V. grew its holdings in Alexion Pharmaceuticals by 820.6% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 9,850 shares of the biopharmaceutical company’s stock worth $1,198,000 after acquiring an additional 8,780 shares in the last quarter. Andra AP fonden acquired a new position in Alexion Pharmaceuticals during the 2nd quarter worth $973,000. Cambridge Investment Research Advisors Inc. acquired a new position in Alexion Pharmaceuticals during the 2nd quarter worth $677,000. Keybank National Association OH grew its holdings in Alexion Pharmaceuticals by 3.6% during the 2nd quarter. Keybank National Association OH now owns 4,872 shares of the biopharmaceutical company’s stock worth $593,000 after acquiring an additional 171 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in Alexion Pharmaceuticals by 1.2% during the 2nd quarter. Principal Financial Group Inc. now owns 335,525 shares of the biopharmaceutical company’s stock worth $40,823,000 after acquiring an additional 4,115 shares in the last quarter. 94.26% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/01/04/insider-selling-alexion-pharmaceuticals-inc-alxn-ceo-sells-2553-shares-of-stock.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.